NEUMORA THERAPEUTICS INC (NMRA)
US6409791000 - Common Stock
These stocks are moving in today's session
Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Thursday's session: top gainers and losers
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
Which stocks are gapping on Thursday?
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops
The company said it plans to investigate a positive signal from female patients.
These stocks are moving in today's pre-market session
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Neumora Plunges After Depression Drug Fails in Final-Stage Study
Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage study for treatment of major depressive disorder.
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score...
Noteworthy Monday Option Activity: COIN, EWCZ, NMRA
Notable Friday Option Activity: UPST, TSCO, NMRA
Commit To Buy Neumora Therapeutics At $5, Earn 105.2% Annualized Using Options
Noteworthy Thursday Option Activity: CMA, NMRA, WMB
Noteworthy Friday Option Activity: NMRA, WMT, CMRE
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of...
Neumora Therapeutics to Participate in Upcoming Conferences in November
Neumora Therapeutics to Participate in Upcoming Conferences in November
WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a...
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a...
Notable Wednesday Option Activity: GM, NMRA, FULC
Commit To Purchase Neumora Therapeutics At $10, Earn 66.1% Annualized Using Options
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET...
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024
NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the second quarter of 2024.
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Neumora Therapeutics (NASDAQ:NMRA) just reported results for the second quarter...
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected in fourth quarter of 2024 Progressing clinical studies in MDD, bipolar depression and...
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of...
Neumora Therapeutics Enters Oversold Territory (NMRA)
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve...